



Europäisches Patentamt
European Patent Office
Office européen des brevets



Publication number: **0 438 750 A2**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 90125035.7

(51) Int. Cl.⁵: **A61K 37/18, A01N 63/02**

(22) Date of filing: 20.12.90

(30) Priority: 23.01.90 JP 13315/90
26.06.90 JP 169636/90

(43) Date of publication of application:
31.07.91 Bulletin 91/31

(84) Designated Contracting States:
DE FR GB IT

(71) Applicant: MORINAGA MILK INDUSTRY CO.,
LTD.
33-1, Shiba 5-chome
Minato-ku, Tokyo(JP)

(72) Inventor: Kobayashi, Susumu
No. 222 Morinaga-Kibougaoaka-Ryo, 118,
Kibougaoaka
Asahi-ku, Yokohama-shi, Kanagawa(JP)
Inventor: Tomita, Mamoru
1-47-6, Higashiasahina, Kanazawa-ku
Yokohama-shi, Kanagawa(JP)
Inventor: Kawase, Kouzou
761-1, Shirakuwa
Urawa-shi, Saitama(JP)
Inventor: Tamura, Yoshitaka
1-4-5, Fujizuka, Kohoku-ku

Yokohama-shi, Kanagawa(JP)
Inventor: Takase, Mitsunori
138-10, Minaminakamaru
Ohmiya-shi, Saitama(JP)
Inventor: Miyakawa, Hiroshi
4-7-21, Ohfuna
Kamakura-shi, Kanagawa(JP)
Inventor: Yamauchi, Koji
No. 405 Garden Heights Kamakura Tamatsuna,
4-2-2
Tamatsuna, Kamakura-shi, Kanagawa(JP)
Inventor: Saito, Hitoshi No. 301
Morinaga-Yurigaoka-Shataku
2-7-4, Yurigaoka
Asoh-ku, Kawasaki-shi, Kanagawa(JP)
Inventor: Abe, Hiroaki
3-43 Urago-cho
Yokosuka-shi, Kanagawa(JP)
Inventor: Shimamura, Seichi
1558, Shinoharacho, Kohoku-ku
Yokohama-shi, Kanagawa(JP)

(74) Representative: Baillie, Iain Cameron et al
c/o Ladas & Parry Isartorplatz 5
W-8000 München 2(DE)

(54) Lactoferrin hydrolyzate for use as an antibacterial agent and as a tyrosinase inhibition agent.

(57) Lactoferrin hydrolyzates, having a decomposition rate between 6 % - 20 % as measured by formol titration, for use as an antibacterial agent which has remarkably potent activity than unhydrolyzed lactoferrin; and lactoferrin hydrolyzates, having a decomposition rate between 4 - 50 % as measured by formol titration, for use as a tyrosinase inhibition agent, which are obtainable by the conventional method for hydrolysis with acid or enzyme, and which are stable to heating.

EP 0 438 750 A2

LACTOFERRIN HYDROLYZATE FOR USE AS AN ANTIBACTERIAL AGENT AND AS A TYROSINASE INHIBITION AGENT

FIELD OF THE INVENTION

The present invention relates to lactoferrin hydrolyzate for use as an antibacterial agent and as a tyrosinase inhibition agent. In other words, the present invention relates to an antibacterial and/or tyrosinase inhibition agent consisting of or containing lactoferrin hydrolyzate as the effective components.

BACKGROUND OF THE INVENTION

Lactoferrin is known as an iron-binding protein occurring in lacrima, saliva, peripheral blood, milk and the like. It has been known that lactoferrin has antibacterial activity against coliform bacillus (*Escherichia coli*), staphylococcus and other enterobacteria (or enteric bacteria) in a concentration within the range of 0.5 - 30 mg/ml (Nonnecke, B. J. and Smith, K. L.; *Journal of Dairy Science*; Vol.67, pp.606; 1984).

It has been considered in general that antibacterial activity of lactoferrin is derived from the situation wherein environmental iron becomes unutilizable to those microorganisms which require iron strongly due to the chelation of lactoferrin with environmental iron. The antibacterial activity of lactoferrin is not necessarily strong enough, thus a considerable quantity of lactoferrin is required to utilize its antibacterial activity, especially when lactoferrin is added to, impregnated into, sticked to, or coated onto other materials. Thus there was a limitation of its usefulness as an antibacterial agent.

It has been attempted to increase antibacterial activity of lactoferrin. For example, it is proposed to use lactoferrin together with lysozyme (Japanese Unexamined Patent Application Gazette No. 62(1987)-249931). It has been also reported that copresence of lactoferrin and secretory IgA may multiplicatively augment antibacterial activity of the former (S. Stephens, J.M. Dolby, J. Montreuil and G. Spik; *Immunology*; Vol. 41; Page 597; 1980).

As far as the best knowledge of the inventors, however, there was no report indicating that chemical treatment of lactoferrin may improve its antibacterial activity.

It has been also known that lactoferrin is unstable to heating, and that the antibacterial activity of lactoferrin can be almost deactivated by heating it at 62.5 °C for 30 minutes, and complete deactivation is resulted by heating it at 70 °C for 15 minutes (Ford, J. E. et al; *Journal of Pediatrics*, Vol. 90, page 29; 1977).

Therefore, sufficient thermal treatment cannot be applied to those materials which contain lactoferrin as an antibacterial agent.

Also it has been known that lactoferrin is not stable to pH variation.

The inventors of the present invention have exerted their efforts to increase antibacterial activity of lactoferrin and to improve stability to heating, and found that hydrolyzate of lactoferrin substances such as native lactoferrin, apolactoferrin, metal saturated lactoferrin, and a mixture thereof show extremely stronger antibacterial activity and excellent stability to heating than unhydrolyzed lactoferrin. The present invention is based on this discovery. The words "native lactoferrin" used herein means that lactoferrin was just isolated from milk and the like, and that no chemical treatment such as iron removing and chelation with metals is made thereon.

Meanwhile it has not been known that lactoferrin and its hydrolyzates have potent tyrosinase inhibition activity.

Tyrosinase is known as an enzyme which may act as a catalyst for oxidization of tyrosin and other monohydric phenols and corresponding dihydric orthophenols with molecular oxygen and which widely occurs in plants such as mushrooms, potatoes, apples as well as in animal tissues. It has been also known that tyrosinase is related to darkening phenomena at an injured portion of plant tissue, and also related to formation of melanine pigment in various tissues of animals, especially in epidermal cells (Editorial Committee of *Encyclopedia Chimica*, *Encyclopedia Chimica*, Vol. 5, page 976, Kyohritsu Shuppan; 1960).

It has been also known that pigmentation of melanin in epidermal cells or mucous membrane in Addison disease is resulted from decrease in secretion of adrenal cortex hormones which antagonize melanotropin which in turn promote tyrosinase activity (Editorial Committee of *Encyclopedia Chimica*, *Encyclopedia Chimica*, Vol. 1, Page 65, Kyohritsu Shuppan; 1960).

Therefore, it has been strongly desired, in the industrial fields of pharmaceutical, cosmetics, food and the like, to develop a tyrosinase inhibition agent for therapy of symptoms resulted from undesirable effects of tyrosinase activity and prevention therefrom. Especially in the cosmetics industry, researches have been

actively made on cosmetics or medicines for external use for effective inhibition of melanin-formation and for whitening of skin, and many products containing tyrosinase inhibition agents have been successively developed. There has been known many tyrosinase inhibition agents, for example, cystein and vitamin C (Yutaka Mishima et al, Fundamental Dermatology, page 258, Asakura Shoten; 1973), kojic acid (Nikkei Sangyo Newspaper, May 24th 1988), arbutin (Ken-ichi Tomita, Preliminary Text for 20th F.J. Seminar, page 21, Fragrance Journal Company, March 14, 1990), products of microorganism belonging to the genus of Trichoderma (Unexamined Japanese Patent Application Gazette No. 2(1990)-145189).

The conventional tyrosinase inhibition agents, however, had more or less defects that they are unstable in the products, they have excessively potent function to melanocyte which produce melanin pigment, and they are too expensive due to difficulty to obtain their raw materials, and they were not satisfiable to use as cosmetics or medicines for external use in the view points of safety, economics, preservability, reliability for whitening effect and so on.

The inventors of the present invention found that lactoferrin, especially its hydrolyzate have potent tyrosinase-inhibition activity. The present invention is also based on this discovery.

OBJECTS OF THE INVENTION

Therefore, it is an object of the present invention to provide lactoferrin hydrolyzate for use as an antibacterial agent.

More particularly, it is an object of the present invention to provide an antibacterial agent consisting of lactoferrin hydrolyzate as the effective component.

It is another object of the present invention to provide antibacterial agent comprising an effective amount of lactoferrin hydrolyzate as an effective component.

It is a still further object of the present invention to provide various products containing the antibacterial and/or tyrosinase inhibition agent.

It is a further object of the present invention to provide a method for treating materials with said antibacterial agent.

It is another object of the present invention to provide lactoferrin hydrolyzate for use as a tyrosinase inhibition agent.

It is a further object of the present invention to provide tyrosinase inhibition agent consisting of lactoferrin hydrolyzate.

It is a still further object of the present invention to provide tyrosinase inhibition agent comprising an effective amount of lactoferrin hydrolyzate as an effective component.

It is a further object of the present invention to provide various types of products comprising an effective amount of lactoferrin hydrolyzate as a tyrosinase inhibition agent.

SUMMARY OF THE INVENTION

In accordance with one aspect of the present invention, lactoferrin hydrolyzate can be used as an excellent antibacterial agent. Preferable range in decomposition rate of lactoferrin hydrolyzate for use as an antibacterial agent is 6 - 20 %, especially 7 - 15 %, as measured by formol titration method (percentage of formol nitrogen to total nitrogen).

In accordance with the other aspect of the present invention, lactoferrin hydrolyzate can be used as tyrosinase inhibition agent. Preferable range in decomposition rate of lactoferrin hydrolyzates for use as tyrosinase inhibition agent is 4 - 50 %, especially 6 - 40 %, as measured by the same method.

Lactoferrin hydrolyzate can be prepared by the conventional method (for example, hydrolysis of lactoferrin by organic or inorganic acids or by enzymes).

Any lactoferrin substance can be used as the starting material for preparation of lactoferrin hydrolyzate, for example, lactoferrin obtainable in the market, native lactoferrin just isolated by the conventional method (for example, ion-exchange chromatography) from mammalian milk, apolactoferrin obtainable by removing iron from native lactoferrin with hydrochloric acid, citric acid and the like, metal saturated lactoferrin obtainable by chelating apolactoferrin with iron, copper, zinc, manganese and the like, or a mixture thereof (hereinafter these lactoferrin substances are abbreviated as LF).

Any mammalian milk (for example, human breast milk as well as cow's, sheep's, goat's, horse's milk and the like) at any lactation stage (for example, colostrum, transitional milk, matured milk, milk in later lactation) can be used as the source of LF. Furthermore, processed milk or byproducts in milk-processing such as skim milk, whey and the like can be used as the source of lactoferrin (hereinafter they are referred to as milk and the like).

Acid hydrolysis can be performed in accordance with the conventional methods, for example, LF is dissolved into water or purified water in a concentration within the range of 0.1 - 20 % (by weight, the same will be applied otherwise indicated), preferably 5 - 15 %, followed by pH adjustment of the resultant solution to 1 - 4, preferably to 2 - 3, and hydrolysis reaction at a proper temperature depending upon the pH of the solution. For instance, when the pH is adjusted to 1 - 2, the solution is heated at 80 - 130 °C, preferably at 90 - 120 °C; when pH is adjusted to 2 - 4, the solution is heated at 100 - 130 °C, preferably at 100 - 120 °C; respectively for 1 - 120 minutes, preferably 5 - 60 minutes until decomposition rate (by formol titration) of LF hydrolyzate is reached to 6 - 20 %, preferably to 7 - 15 %.

Enzymatic hydrolysis can be performed in accordance with the conventional method, for example, LF is dissolved into water or purified water in a concentration between 0.5 - 20 %, preferably 5 - 15 %, followed by pH adjustment of the resultant solution into the optimum pH range, and enzymatic hydrolysis under proper conditions, for example, a temperature between 15 - 55 °C, preferably between 30 - 50 °C for 30 - 600 minutes, preferably for 60 - 300 minutes. The reacted mixture is neutralized, followed by deactivation of the enzyme in accordance with the conventional method.

In case of preparation of an antibacterial agent, any acidic enzymes such as Molsin F (trademark; by Seishin Seiyaku; optimum pH: 2.5 - 3.0), swine pepsin (by Wakoh Junyaku Kogyo; optimum pH: 2 - 3), Sumizyme AP (trademark; by Shin Nihon Kagaku; optimum pH: 3.0), Amano M (trademark; by Amano Seiyaku; optimum pH: 3.0) and the like can be used individually or in any combination thereof. Among them, good results were obtained by use of swine pepsin and Sumizyme AP.

In case of preparation of tyrosinase inhibition agent, there is no limitation to the enzymes to be used, for example, Amano A (trademark, by Amano Seiyaku; optimum pH: 7.0), trypsin, exopeptidase originated from lactic acid bacteria recited in Japanese Examined Patent Application Gazette No. 48(1973)-43878 and commercial Shohyu-enzyme (soy sauce enzyme) comprising exopeptidase (by Tanabe Seiyaku) can be used, in addition to those enumerated above, individually or in any combination thereof.

The quantity of enzymes to be used may be 0.1 - 5.0 %, preferably 0.5 - 3.0 % to the substrate used.

Regardless of the method of hydrolyzation, the resultant solution containing LF hydrolyzate is cooled by the conventional method, if necessary, followed by neutralization, demineralization, and decolorization. The resultant solution can be used as a liquid product as it is or if required, the solution is further concentrated and/or dried to obtain a concentrated liquid product or a powdery product.

The conditions of hydrolysis referred in the above are not critical, but can be modified depending upon the temperature, the period of time, the pressure as well as the kind and quantity of the acid or enzyme used.

LF hydrolyzate in the present invention is a mixture of the decomposed substances having different molecular weights.

Thus obtained LF hydrolyzate is highly stable to heating, and is excellent in antibacterial activity compared to unhydrolyzed lactoferrin, and have tyrosinase inhibition activity.

DETAILED DESCRIPTION OF THE INVENTION

Now some tests will be described hereunder for exemplifying the utility of LF hydrolyzate as an antibacterial agent.

[TEST 1]

The purpose of this test is to show relationships between decomposition rate of LF hydrolyzate and antibacterial activity.

1) METHOD

1-1) PREPARATION OF SAMPLES

Native LF sold in the market (by Oleofina, Belgium) was dissolved into purified water in 5 % concentration. The resultant solution was divided into several lots which were adjusted into different pH, 1, 2, 3 and 4 by adding 1 M hydrochloric acid thereto. The resultant solutions having different pH were subjected to hydrolysis reaction under different conditions in a combination of a temperature between 60 - 130 °C and a time between 5 - 60 minutes to thereby prepare samples of LF hydrolyzate having different decomposition rates as shown in Table 1.

1-2) MEASUREMENT OF HYDROLYZATION RATE

Decomposition rate (%) of the resultant LF hydrolyzate was determined in such a manner that the quantity of formol nitrogen in the respective samples was measured by formol titration method, then the resultant values were applied to the following formula.

$$\text{decomposition rate (\%)} = 100 \times (A / B)$$

(wherein A denotes the quantity of formol nitrogen, B denotes the quantity of total nitrogen)

1-3) PREPARATION OF PRE-CULTURE AND CULTURE MEDIUM

1-3-1) PREPARATION OF PRE-CULTURE

From the stock culture of *Escherichia coli*, a loop of bacterial cells was taken out with a platinum loop and smeared onto a standard plate agar medium (by Nissui Seiyaku), followed by incubation at 35 °C for 16 hours under aerobic condition. The colonies grown on the surface of the culture were collected with a platinum loop and suspended into sterilized saline solution to prepare pre-culture having optical density of 1.0 (at 660 nm) measured by a spectrophotometer (by Hitachi Seisakusho).

1-3-2) PREPARATION OF BASIC CULTURE MEDIUM

Basic culture medium (liquid culture medium) was prepared with dissolving bactocasitone (by Difco) into purified water in 1 % concentration, adjusting the pH of the resultant solution to 7.0 by 1 M sodium hydroxide, then sterilized at 115 °C for 15 minutes.

1-3-3) PREPARATION OF TEST AND CONTROL CULTURE MEDIA

The solutions of LF hydrolyzates previously prepared in item 1-1) were respectively filtrated with membrane filters (by Advantech) to remove microorganisms which might be included therein. Different quantities of each of filtrated solutions of LF hydrolyzates were respectively added to a portion of the basic culture medium to give 6 lots of test culture media containing LF hydrolyzate in different concentrations for each LF hydrolyzate, having different decomposition rates as shown in Table 1. Control culture media containing unhydrolyzed LF in different concentration were also prepared in the same manner as in the test culture media.

1-3-4) TEST FOR ANTIBACTERIAL ACTIVITY

To each of the test and control culture media, the pre-culture was inoculated in 1 % concentration, followed by incubation at 35 °C for 16 hours. The proliferation inhibition rate was determined by measuring optical density of the culture broth in the same manner as previously described and calculated in accordance with the following formula.

$$\text{proliferation inhibition rate (\%)} = 100 - (A / B \times 100)$$

(wherein A denotes the difference of optical densities of the test culture media before and after 16 hours incubation, B denotes the difference of optical densities of the control culture media before and after 16 hours incubation respectively)

2) RESULTS OF THE TEST

The results are shown in Table 1.

Table 1

decomposition rate (%)	concentration (ppm)					
	25	50	100	250	500	1000
control	0	0	0	16	42	65
6	8	26	40	94	100	100
7	17	41	98	100	100	100
8	21	60	100	100	100	100
9	28	69	100	100	100	100
10	23	74	100	100	100	100
11	18	59	100	100	100	100
12	11	45	100	100	100	100
13	4	40	94	100	100	100
14	2	38	86	100	100	100
15	0	16	73	97	100	100
16	0	9	47	84	96	100
18	0	2	32	68	89	100
20	0	0	20	56	82	93
25	0	0	2	9	25	60
30	0	0	0	0	1	5

Note: the values indicate proliferation inhibition rates (%).

As will be seen from the Table 1, the unhydrolyzed LF (control) showed antibacterial activity when LF was added more than 250 ppm, but complete inhibition could not be achieved even when 1000 ppm of LF was added (weak antibacterial activity). In contrast to this, LF hydrolyzate having 10 % decomposition rate showed potent antibacterial activity at the concentration of 25 ppm, and proliferation of *E. coli* was completely inhibited at a concentration over 100 ppm. It will be understood that LF hydrolyzate of decomposition rate between 6 - 20 %, especially between 7 - 15 %, prepared by acid hydrolysis of LF have remarkably potent antibacterial activity in comparison with unhydrolyzed LF.

[TEST 2]

Ten samples of powdery LF hydrolyzates, nos. 1 - 10, were prepared in such a manner that each of 5 kinds of commercial enzymes was added to 5 % aqueous solution of commercial LF (by Oleofina), followed by adjustment of pH to the optimum pH of the respective enzymes, enzymatic hydrolyzation at 37 °C for different reaction times, adjustment of pH of the hydrolyzed solutions to 7, deactivation of the enzymes at 80 °C for 10 minutes, and lyophilization of the resulted solutions. The kinds of enzymes and their quantities added to the substrate (LF), reaction times of hydrolyzation and decomposition rates of the respective samples are shown in Table 2. The decomposition rates were determined by the same method as in Test 1.

2) RESULT

The results of this test are shown in Table 2.

Table 2

sample No.	enzymes used	quantity of enzyme (%)	reaction time (minutes)	decomposition rate (%)
1	Molsin F	0.1	120	12.4
2	Molsin F	1.0	300	14.7
3	swine pepsin	0.3	30	6.3
4	swine pepsin	3.0	180	11.4
5	Sumizyme AP	1.0	180	10.3
6	Sumizyme AP	3.0	180	13.5
7	Amano M	0.1	60	5.9
8	Amano M	3.0	120	12.6
9	Trypsin	3.0	180	10.3
10	Trypsin	6.0	360	12.5

As will be seen from Table 2, decomposition rates of LF hydrolyzate by acidic protease such as Molsin F, swine pepsin, Sumizyme AP, and Amano M fall between 5.9 - 14.7 %, and those by trypsin which is a neutral protease were 10.3 - 12.5 %.

[Test 3]

The purpose of this test is to exemplify antibacterial activity of LF hydrolyzate prepared by acid hydrolysis.

Antibacterial activity against E. coli of LF hydrolyzate having 12 % decomposition rate prepared in the same manner as in Example 2 (hydrolyzation by citric acid) and that of unhydrolyzed LF were determined in the same manner as in Test 1.

The results are shown in Table 3.

Table 3

sample	quantity added (ppm)					
	25	50	100	250	500	1000
unhydrolyzed LF	0	0	5	16	74	85
LF hydrolyzate	12	41	100	100	100	100

Note: The values indicate proliferation inhibition rates (%).

From the results of the foregoing test, it is exemplified that LF hydrolyzate prepared by organic acid hydrolysis, and inorganic acid hydrolysis have antibacterial activity.

[TEST 4]

The purpose of this test is to exemplify effectivity of the method for treatment of a material with antibacterial agent in accordance with the present invention.

A quantity of sliced vegetables sold in the market was divided into three parts, each of the parts was

respectively dipped into 1 % aqueous solution of LF hydrolyzate prepared in the same manner as in Example 1 (hydrolyzed by inorganic acid, decomposition rate: 9 %), unhydrolyzed LF solution (control) and sterilized water (control) for 30 seconds. Each of the treated samples was drained then preserved at 5 °C for observation. Viable bacterial count of the samples was periodically determined by the conventional method.

The results of this test are shown in Table 4.

Table 4

Samples	preservation period (hours)			
	0	12	24	36
sterilized water	5.1×10^3	4.9×10^4	5.0×10^5	9.2×10^5
unhydrolyzed LF	5.1×10^3	2.0×10^4	1.8×10^5	2.2×10^5
LF hydrolyzate	5.1×10^3	1.1×10^3	1.5×10^3	1.6×10^3

Note: The values indicate viable bacterial counts per 1 g of sliced vegetables.

As will be seen from the Table 4, it is exemplified that LF hydrolyzate has remarkably stronger antibacterial activity than unhydrolyzed LF when they are used for treatment of materials.

[Test 5]

The purpose of this test is to exemplify the effectiveness of inclusion of LF hydrolyzate in a food as the effective component for antibacterial activity.

A quantity of raw milk was sterilized at 65 °C for 30 minutes and dispensed into test tubes by 10 ml. To each of the test tubes, LF hydrolyzate having 9 % decomposition rate (prepared in Example 1) or unhydrolyzed LF were added and homogeneously mixed in 0.1 % concentration, and sealed to prepare samples No. 1 and No. 2. A sample which contains raw milk only was prepared as a control sample. These samples were preserved at 25 °C to determine preservable days during which coagulation of raw milk was not observed.

The results were that coagulation was observed in sample No. 1 on the 9th day, in sample 2 on the 4th day, and in control sample on the 2nd day. This means that LF hydrolyzate has excellent antibacterial activity. Meanwhile, organoleptic test was carried out with respect to the control sample and sample No. 1 immediately after preparation of the samples, and confirmed that there was no difference in taste and appearance therebetween.

[TEST 6]

The purpose of this test is to exemplify antibacterial activity of LF hydrolyzate prepared by enzymatic hydrolysis.

1) METHOD

Aqueous solutions of 10 kinds of LF hydrolyzate (prepared using different enzymes) and an aqueous solution of unhydrolyzed LF prepared in the same manner as in test 2 were filtrated with membrane filters (by Advantec) to remove bacterial cells which might be contaminated therein. Each of the solutions were added to basic culture media (the same with that in Test 1) in different concentrations (50, 100, 250, 500, and 1000 ppm) to prepare test cultures and control cultures.

Antibacterial activity was tested for these cultures in the same manner as in test 1.

2) RESULTS

The results are shown in Table 5.

Table 5

sample No.	proliferation inhibition rate (%)				
	quantity of LF hydrolyzate added (ppm)				
	50	100	250	500	1000
1	20	78	100	100	100
2	2	54	96	100	100
3	0	5	24	78	100
4	41	97	100	100	100
5	35	93	100	100	100
6	16	62	100	100	100
7	0	3	15	38	61
8	26	65	84	100	100
9	0	0	0	0	0
10	0	0	0	0	0
control	0	0	7	25	46

As will be seen from Table 5, unhydrolyzed LF (control) showed weak antibacterial activity at addition of 250 ppm, and complete inhibition against proliferation of *E. coli* could not be achieved even by addition of 1000 ppm. LF hydrolyzate having decomposition rate over 10 % resulted from hydrolysis by Molsin F, swine pepsin, Sumizyme AP and Amano M all of which are acidic protease showed potent antibacterial activity at presence of only 100 ppm, and presence over 250 ppm may inhibit proliferation of coliform bacillus perfectly. On the other hand, LF hydrolyzate resulted from hydrolysis by trypsin which is a neutral protease did not show any antibacterial activity even at presence of 1000 ppm.

It was exemplified that LF hydrolyzate resulted from hydrolysis by acidic protease having decomposition rate more than 10 % has stronger antibacterial activity against coliform bacillus than unhydrolyzed LF.

[TEST 7]

The purpose of this test is to confirm antibacterial activity of a composition containing hydrolyzate of metal saturated LF.

Antibacterial activity of hydrolyzate of iron saturated LF was tested in the same manner as in test 5, except that hydrolyzate of iron saturated LF prepared in the same manner as in Example 5 and cow's milk sold in the market were used.

Three kinds of samples, one is added hydrolyzate of Fe-LF, another one is added unhydrolyzed LF and the rest is added nothing, were respectively distributed into 3 test tubes (in total 9) and preserved at 25 °C for observation of any change in appearance.

The results are shown in Table 6.

Table 6

sample	preservation (day)				
	0	3	7	10	14
hydrolyzate of Fe-LF 1	no change	no change	no change	no change	no change
2	no change	no change	no change	no change	no change
3	no change	no change	no change	no change	no change
unhydrolyzed Fe-LF 1	no change	no change	no change	no change	coagulated
2	no change	no change	no change	no change	coagulated
3	no change	no change	no change	no change	coagulated
control (added nothing) 1	no change	no change	no change	coagulated	coagulated
2	no change	no change	no change	no change	coagulated
3	no change	no change	no change	coagulated	coagulated

All of the samples (milk) added hydrolyzate of Fe-LF did not show any change in appearance on the 14th day after initiation of the test. All of the samples added unhydrolyzed LF did not show any change in appearance until 10th day after initiation of the test, but all of the samples showed coagulation on the 14th day. In control samples, 2 samples showed coagulation on the 10th day, and all of the samples coagulated on the 14th day. It was exemplified that hydrolyzate of Fe-LF have excellent antibacterial activity in comparison with unhydrolyzed LF.

[TEST 8]

The purpose of this test is to confirm antibacterial activity of LF hydrolyzate under the presence of iron. Antibacterial activity was tested with respect to some samples used in Test 6, i. e. sample Nos. 1, 2, 5, 6 and the sample containing unhydrolyzed LF (control) in the same manner as in Test 6, except that 0.01 mM of ferrous sulfate (FeSO_4) was further added to the respective culture media.

The results are shown in Table 7.

Table 7

sample No.	proliferation inhibition rate (%)				
	quantity of LF hydrolyzate (ppm)				
	50	100	250	500	1000
1	13	59	100	100	100
2	0	26	87	100	100
5	27	65	86	100	100
6	14	40	93	100	100
control	0	0	0	0	0

Antibacterial activity of unhydrolyzed LF was deactivated under the presence of 0.01 mM of ferrous sulfate, however, all of the LF hydrolyzate resulted from hydrolyzation by acidic protease maintained its antibacterial activity under the presence of 0.01 mM of ferrous sulfate.

Now some tests will be described hereunder for exemplifying the utility of LF hydrolyzate as a

tyrosinase inhibition agent.

[TEST 9]

- 6 The purpose of this test is to exemplify tyrosinase inhibition activity of LF hydrolyzate resulted from acid hydrolysis of LF.

1) PREPARATION OF SAMPLES

- 10 Native LF sold in the market (by Oleofina, Belgium) was dissolved into purified water in 5 % concentration. The resultant solution was divided into several lots which were adjusted into different pH values, 1, 2, 3 and 4 by adding 1 M hydrochloric acid thereto. The resultant solutions having different pH values were subjected to hydrolysis reaction under different conditions in a combination of a temperature between 60 - 130 °C and a reaction time between 5 - 60 minutes, to thereby prepare 8 kinds of solutions of
15 LF hydrolyzate having different decomposition rates as shown in Table 8. The resultant solutions were adjusted to pH 7 with 1 M sodium hydroxide, then lyophilized to thereby obtain 8 kinds of powdery LF hydrolyzate in different decomposition rates between 4 - 30 %.

2) METHOD

20

2-1) DETERMINATION OF DECOMPOSITION RATE

- Decomposition rate (%) of the resultant LF hydrolyzate was determined in such a manner that the quantity of formol nitrogen in the respective samples was measured by formol titration method, then the
25 resultant values were applied to the following formula.

$$\text{Decomposition rate} = 100 \times (A / B)$$

(wherein A denotes quantity of formol nitrogen, and B denotes quantity of total nitrogen)

30

2-2) MEASUREMENT OF TYROSINASE INHIBITION ACTIVITY

2-2-1) PREPARATION OF VARIOUS SOLUTIONS

- 35 2-2-1-1) PREPARATION OF SUBSTRATE SOLUTION

L-tyrosin as guaranteed grade reagent (by Wakoh Junyaku Kogyoh) was dissolved into 0.1 M phosphate buffer solution in 0.045 % (W/V) concentration.

- 40 2-2-1-2) PREPARATION OF ENZYME SOLUTION

Tyrosinase derived from mushroom (by Sigma, 3,000 unit/mg) was dissolved into 0.1 M phosphate buffer solution (pH 7.0) in 0.1 % (W/V) concentration.

- 45 2-2-1-3) PREPARATION OF COPPER ION SOLUTION

Copper sulfate as guaranteed grade reagent (by Wakoh Junyaku Kogyoh) was dissolved into purified water in 1 % (W/V) concentration.

- 50 2-2-1-4) PREPARATION OF SAMPLE SOLUTION

- Each of the solutions of LF hydrolyzate previously prepared in item 1) in different decomposition rates was respectively dissolved into 0.1 M phosphate buffer solution (pH 7.0) to prepare sample solutions in 8 different concentrations, so that when the sample solutions were added in the proportions described in the
55 next item 2-2-2), 8 lots of test samples in different concentrations as shown in Table 8 were prepared for each LF hydrolyzate having different decomposition rates.

2-2-2) ENZYMATIC REACTION

Each of the resultant sample solutions, previously prepared substrate solution and the copper ion solution, which are previously heated to 37 °C, were mixed in a test tube in the proportion as follows:

sample solution 1.0 ml
substrate solution 0.9 ml
copper ion solution 0.02 ml

To each of the mixtures, 0.08 ml of enzyme solution which was previously heated to the same temperature was added (in total 2.0 ml), and enzymatic reaction was performed at 37 °C for 3 minutes. After the reaction, 2 ml of 30 % acetic acid solution was added to each of the reaction mixture to terminate enzymatic reaction, then absorbancy of the respective reaction mixtures was measured with a spectrophotometer at the wave length of 640 nm (the values of the absorbancy are denoted as B). As a control, a solution was prepared substituting 1.0 ml of 0.1 M phosphate buffer solution for sample solution, and the resultant solution was subjected to enzymatic reaction and measurement of absorbancy in the same manner as test samples No. 1 - No. 8 (the value of the absorbancy was denoted as A). In case of that the sample solution was muddy, absorbancy of a corresponding mixture which has the same composition as the muddy sample solution in question except that the enzyme solution was substituted with 0.08 ml of 0.1 M phosphate buffer solution was measured (the value of the absorbancy are denoted as C), and the value of C is reduced from the value B to obtain the difference of absorbancy of the reaction mixture before and after enzymatic reaction.

The measured values were applied to the following formula to obtain tyrosinase inhibition rate (%).

$$\text{inhibition rate} = 100 \times [1 - (B - C) / A]$$

3) RESULTS

The results are shown in Table 8.

Table 8

sample No.	decomposition rate (%)	concentration of LF hydrolyzate (%)							
		0.02	0.05	0.1	0.3	0.4	0.5	1.0	2.0
control	0	0	0	0	0	0	0	0	0
1	4	-	-	3	11	-	19	30	50
2	6	11	29	59	80	-	100	-	-
3	8	9	33	61	79	-	100	-	-
4	10	16	33	63	85	-	100	-	-
5	15	10	32	61	81	-	100	-	-
6	20	9	30	62	77	-	100	-	-
7	25	9	28	60	82	-	100	-	-
8	30	13	31	58	81	-	100	-	-

Note: tyrosinase inhibition rate (%)

Sample No. 1 which had 4 % decomposition rate showed about 10 % tyrosinase inhibition rate with addition of 0.3 % of the LF hydrolyzate. The inhibition activity increased as the concentration of LF hydrolyzate increased, 30 % inhibition rate with addition of 1 % LF hydrolyzate, and 50 % inhibition rate

with addition of 2 % of the LF hydrolyzate.

On the other hand, Samples No. 2 - 8 having decomposition rates 6 - 30 % showed about 30 % inhibition rate with addition of LF hydrolyzate only in 0.05 % concentration. The inhibition rate was increased as the concentration of LF hydrolyzate was increased, about 60 % with 0.1 % concentration, 80 % with 0.3 % concentration, and 100 % with 0.5 % concentration.

It was also confirmed that acid hydrolyzate of other LF substances such as apolactoferrin, zinc-, copper-, and iron-LF showed similar tyrosinase inhibition rate.

[TEST 10]

The purpose of this test is to exemplify tyrosinase inhibitory efficacy of LF hydrolyzate resulted from enzymatic hydrolysis of LF.

1) PREPARATION OF SAMPLE

LF sold in the market (by Oleofina) was dissolved into purified water in 5 % concentration. The resultant LF solution was distributed into 8 lots to which different combination of enzymes comprising swine p p sin, Amano A and soy source enzyme containing peptidase sold in the market was added in different concentration between 0.1 - 6 % to prepare samples Nos. 9 - 16. The resultant mixtures were kept at 37 °C for different reaction times between 10 minutes - 24 hours for enzymatic reaction, the reacted solutions were adjusted to pH 7, heated to 80 °C for 10 minutes for deactivation of enzymes, then lyophilized to obtain LF hydrolyzate having different decomposition rates between 6 - 50 %.

2) METHOD

Decomposition rates and tyrosinase inhibition rates of the respective LF hydrolyzate were measured in the same manner as in Test 9.

3) RESULTS

The results are shown in Table 9.

Table 9

sample No.	decomposition rate (%)	concentration of LF hydrolyzate (%)						
		0.02	0.05	0.1	0.3	0.5	1.0	2.0
control	0	0	0	0	0	0	0	0
9	6	10	28	55	82	100	-	-
10	10	8	32	60	79	100	-	-
11	15	9	33	58	80	100	-	-
12	20	12	31	62	78	100	-	-
13	30	9	30	61	83	100	-	-
14	40	11	28	60	80	100	-	-
15	45	-	-	2	11	23	35	54
16	50	-	-	3	10	27	33	52

Note: tyrosinase inhibition rate (%)

Sample Nos. 9 - 14 which had a decomposition rate between 6 - 40 % showed about 30 % tyrosinase inhibition rate with addition of 0.05 % LF hydrolyzate. The inhibition activity increased as the concentration of LF hydrolyzate increased, about 60 % inhibition rate was achieved with addition of 0.1 % LF hydrolyzate,

about 80 % inhibition rate with addition of 0.3 %, and 100 % inhibition rate with addition of 0.5 % LF hydrolyzate.

On the other hand, Sample Nos. 15 and 16 having decomposition rates of 45 and 50 % respectively showed about 10 % inhibition rate at 0.3 % concentration of LF hydrolyzate. The inhibition rate was increased as the concentration of LF hydrolyzate was increased, about 30 % inhibition rate with 1 % concentration, about 50 % inhibition with 2 % concentration.

It was also confirmed that enzymatic hydrolyzate of other LF substance, that is apolactoferrin, metal saturated LF chelated with metals such as zinc, copper, iron and the like showed substantially the same tyrosinase inhibition rate. More specifically it was found that tyrosinase inhibition rate mainly depends upon decomposition rate of LF hydrolyzate.

Now, some examples will be described for better understanding of the present invention.

EXAMPLE 1

To 950 g of purified water, 50 g of native LF sold in the market (by Oleofina, Belgium) was dissolved, then the pH of the resulted solution was adjusted to 2 with 1 M of hydrochloric acid. The resultant solution was heated to 120 °C for 15 minutes for acid hydrolysis, then cooled, thereby about 1000 g of 5 % solution of LF hydrolyzate having antibacterial activity was obtained. The decomposition rate of the LF hydrolyzate was 9 % (determined by the same method as in Test 1).

EXAMPLE 2

To 850 g of purified water, 150 g of native LF sold in the market (by Oleofina, Belgium) was dissolved. The resultant solution was adjusted to pH 3 with 1 M of citric acid, then heated to 130 °C for 60 minutes for hydrolyzation. The resulted solution was cooled, adjusted to pH 7 with 1 M sodium hydroxide, filtrated, demineralized, then lyophilized (freezedried) thereby about 45 g of powdery LF hydrolyzate having antibacterial activity was yielded.

The decomposition rate of this LF hydrolyzate was 12 % (determined by the same method as in Test 1).

EXAMPLE 3

1) PREPARATION OF Fe SATURATED LF

To 180 g of purified water, 20 g of native LF sold in the market (by Oleofina, Belgium) was dissolved. To the resultant solution, 200 mg of $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ was added. After maintaining at 25 °C for 12 hours, unreacted Fe was removed from the reacted solution by ultrafiltration module SEP-1013 (trademark, by Asahikasei), then the resultant filtrate was lyophilized to thereby obtain about 19 g of iron saturated LF.

2) HYDROLYSIS OF Fe SATURATED LF

To 285 g of purified water, 15 g of iron saturated LF was dissolved, the pH of the resulted solution was adjusted to 1.0 with 2 M hydrochloric acid, heated at 90 °C for 15 minutes for hydrolysis, then cooled, thereby about 300 g of about 5 % solution of LF hydrolyzate having antibacterial activity was yielded.

The decomposition rate of the resulted LF hydrolyzate was 7 % (determined by the same method as in Test 1).

EXAMPLE 4

1) PREPARATION OF COLUMN

In a column (id. 10 cm), 500ml of Sepabeads FP-CM13 (trademark, by Mitsubishi Kasei) having a carboxymethyl group as an ion-exchange group was filled, then 10 % aqueous solution of sodium chloride was passed through the resulted column. The column was washed with water to thereby obtain Na-type ion-exchanger.

2) PREPARATION OF NATIVE LF

To the resultant column, 60 l of cheese whey (pH 6.5) originated from goat milk was introduced at 4 °C at the flow rate of 4 l/hour. After the column was washed with water to remove the unadsorbed components of the cheese whey, the adsorbed component of the cheese whey was eluted with 10 % aqueous solution of sodium hydroxide at the flow rate of 5 l/hour to thereby obtain about 5 l of eluate. The resultant eluate was concentrated with ultra-filtration module SEP-1013 (trademark, by Asahikasei) then water was added thereto to remove sodium chloride to thereby obtain about 200 ml of LF solution containing 1 % goat LF.

3) ACID HYDROLYSIS

The resultant LF solution was adjusted to pH 2.0 with 1 M hydrochloric acid, heated to 120 °C for 20 minutes, then cooled, to thereby obtain about 200 g of 1 % solution of LF hydrolyzate having antibacterial activity. The decomposition rate of the LF hydrolyzate was 10 % (determined by the same method as in Test 1).

EXAMPLE 5

1) PREPARATION OF Fe SATURATED LF

To 9 kg of purified water, 1 kg of native LF (by Oleofina, Belgium) was dissolved. To the resultant solution, 10 g of $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ was added, maintained at 25 °C for 12 hours. From the resultant solution, unreacted iron was removed by ultrafiltration module SEP-1013 (trademark, by Asahikasei).

2) ENZYMATIC HYDROLYSIS

After adjusted the resultant solution to pH 3.5 with 0.5 N hydrochloric acid, 10 g of Molsin F (trademark, by Seishin Seiyaku, 42,000 unit/g of protein) sold in the market was added to the solution and homogeneously mixed. The resultant mixture was maintained at 37 °C for 180 minutes, neutralized, heated to 85 °C for 10 minutes for deactivation of the enzyme, then cooled, thereby about 10 kg of LF hydrolyzate solution having antibacterial activity was yielded.

The decomposition rate of the resultant LF hydrolyzate was 13.5 % (determined by the same method as in Test 1).

EXAMPLE 6

To 9 kg of purified water, 1 kg of native LF (by Oleofina, Belgium) was dissolved. The resultant solution was adjusted to pH 2.5 with 2 M citric acid, added 30 g of swine pepsin sold in the market (10,000 unit/g of protein: by Wakoh Junyaku Kogyo), homogeneously mixed, maintained at 37 °C for 180 minutes for hydrolysis, heated to 85 °C for 10 minutes for deactivation of the enzyme, cooled, concentrated by the conventional method to thereby obtained about 10 kg of a solution of the LF hydrolyzate having antibacterial activity.

The decomposition rate of the resultant LF hydrolyzate was 11.3 % (determined by the same method as in Test 1).

EXAMPLE 7

1) PREPARATION Cu SATURATED LF

Copper saturated LF was prepared as follows. To 50 l of goat skim milk, 5 l of 0.1 M citric acid solution containing 0.003 M ferric chloride (FeCl_3) was added and homogeneously mixed. To the resultant solution, 5 l of CM-Sephadex C-50 (H^+ type, by Pharmacia) was added and stirred for 1 hour. After removing unadsorbed components of the goat skim milk by washing the ion-exchange resin with water, the resin was suspended in 0.05 M tris-hydrochloride buffer solution (pH 8.0). The resultant suspension was filled in a column (20 x 50 cm), then washed with the same buffer solution. The adsorbed components of goat skim milk were eluted with 0.05 M tris-hydrochloric acid buffer solution containing sodium chloride in a gradient of 0 - 2 M to thereby collect about 800 ml of LF fraction. The resultant LF fraction was concentrated into 150 ml with ultrafiltration membrane PM-10 (trademark, by Amicon), then dialyzed against 0.05 M tris-acetate buffer solution (pH 8.2) containing 0.5 M sodium chloride. The resultant dialyzed

solution was introduced into a column (10 x 30 cm) filled with copper chelating Sephalose 6B (trademark, by Pharmacia) which was previously equilibrated with the same buffer solution to adsorb LF. After washing the column with the same buffer solution, the adsorbate was eluted with acetate buffer solution (pH 4.0) containing 0.5 M sodium chloride. The resultant eluate was dialyzed against purified water, then lyophilized to thereby obtain about 2 g of powdery LF.

2) ENZYMATIC HYDROLYSIS

To 17 g of purified water, 2 g of the resulted powdery LF was added, the resultant solution was adjusted to pH 3.5 with 1 M lactic acid. To the resultant solution, 60 mg of Sumizyme AP sold in the market (trademark, by Shinnihon Kagakukougyo, 50,000 unit/g of protein) was homogeneously added, maintained at 50 °C for 180 minutes, neutralized, then resultant reaction mixture was heated to 85 °C for 10 minutes for deactivation of the enzyme, cooled, concentrated then lyophilized to thereby obtain about 2 g of powdery LF hydrolyzate having antibacterial activity.

The decomposition rate of the resulted LF hydrolyzate was 13.8 % (determined by the same method as in test 1).

Example 8

LF solution was prepared by dissolving 80 g of LF sold in the market (by Oleofina) into 1000 ml of purified water, then pH of the resultant LF solution was adjusted to 2 with 1 M hydrochloric acid. The resultant solution was heated to 115 °C for 10 minutes, the solution was adjusted to pH 7 with 1 M sodium hydroxide solution, then lyophilized to thereby obtain about 77 g of LF hydrolyzate powder having 15 % decomposition rate as measured by the same method as in Test 1.

Having homogeneously mixed 50 g of the resultant LF hydrolyzate, 900 g of glycine (by Wakoh Junyaku Kogyo), and 50 g of lysozyme (by Wakoh Junyaku Kogyo), about 1000 g of a tyrosinase inhibition agent to be used for keeping freshness of food was prepared.

Tyrosinase inhibition rate of 20 % aqueous solution of the resultant tyrosinase inhibition agent was 100 % measured in the same method as in Test 9.

EXAMPLE 9

After dissolving 270 g of LF sold in the market (by Oleofina) into 6300 ml of purified water, the resultant solution was adjusted its pH to 2.5 with 10 % aqueous solution of citric acid, and kept at room temperature for 1 hour for iron removing reaction. The reacted solution was subjected to ultrafiltration, and the resultant concentrate was lyophilized to thereby obtain about 260 g of apolactoferrin.

Sixty g of the resultant apolactoferrin was dissolved into 1000 ml of water, the resultant solution was adjusted to pH 3 with 2 M phosphoric acid solution. The resultant solution was heated to 121 °C for 25 minutes, adjusted its pH to 7 with 1 M sodium hydroxide solution, then lyophilized to thereby obtain about 55 g of powdery LF hydrolyzate having 23 % decomposition rate measured by the same method as in Test 9.

Having homogeneously mixed 20 g of the resultant LF hydrolyzate, 400 g of propylene glycol (by Wakoh Junyaku Kogyo), 4 g of oleyl alcohol (by Wakoh Junyaku Kogyo), 200 g of ethanol (by Wakoh Junyaku Kogyo) and 3376 g of purified water, about 4000 g of tyrosinase inhibition agent for use in cosmetics was obtained.

Apparent inhibition rate against tyrosinase of the resultant agent was 75 %, but substantial inhibition rate against tyrosinase was calculated 100 % in consideration of LF hydrolyzate concentration.

EXAMPLE 10

Having homogeneously mixed 100 g of LF sold in the market (by Oleofina) and 1000 ml of purified water, pH of the resultant solution was adjusted to 2 with 1 M hydrochloric acid. To the resultant solution, 5 g of swine pepsin sold in the market (by Wakoh Junyaku Kogyo) was added and reacted at 37 °C for 60 minutes. The reacted solution was heated to 80 °C for 10 minutes for deactivation of the enzyme, then lyophilized to thereby obtain about 95 g of LF hydrolyzate having 12 % decomposition rate measured by the same method as in Test 9.

About 2000 g of tyrosinase inhibition agent for cosmetic use was prepared by homogeneously mixing 30 g of the resultant LF hydrolyzate, 200 g of propylene glycol (by Wakoh Junyaku Kogyo), 2 g of oleyl

alcohol (by Wakoh Junyaku Kogyo), 100 g of ethanol (by Wakoh Junyaku Kogyo) and 1668 g of purified water.

Tyrosinase inhibition rate of the resultant tyrosinase inhibition agent was 100 % as measured by the same method as in Test 9.

5

EXAMPLE 11

One hundred and fifty g of LF sold in the market (by Oleofina) was dissolved into 150 g of purified water, pH of the resultant solution was adjusted to 8 with 1 M sodium hydroxide solution, then pasteurized at 60 °C for 10 minutes. The resultant solution was cooled to 50 °C, and 15 g of trypsin (by Nobo) and 30 g of soy sauce enzyme containing peptidase sold in the market (by Tanabe Seiyaku) were added to react at 50 °C for 5 hours. The reacted solution was heated at 80 °C for 10 minutes for deactivation of the enzymes, lyophilized to thereby obtain about 145 g of powdery LF hydrolyzate having 38 % decomposition rate as measured by the same method as in Test 9.

Having homogeneously mixed 12 g of sodium hyaluronate (by Wakoh Junyaku Kogyo), 15 g of plasenta extract (by Botoger, West Germany), 10 g of glycelin (by Wakoh Junyaku Kogyo) and 962 g of purified water, about 1000 g of tyrosinase inhibition agent was obtained.

Tyrosinase inhibition rate of the resultant agent was 100 % measured by the same method as in Test 9.

EXAMPLE 12

About 78 g of Fe-LF was prepared by dissolving 90 g of LF sold in the market (by Oleofina) into 2100 ml of purified water, the resultant solution was reacted with 755 ml of 2.6 mM aqueous solution of ferrous sulfate at room temperature for 24 hours, the resultant reacted solution was subjected to ultrafiltration, then the resultant concentrate was lyophilized.

Forty g of the resultant Fe-LF was dissolved into 500 ml of purified water, pH of the resultant solution was adjusted to 3 with 1 M hydrochloric acid solution. To the resultant solution, 5 g of Sumizyme AP (by Shin Nihon Kagaku) was added and the resultant mixture was subjected to hydrolysis at 30 °C for 3 hours. The reacted mixture was heated at 80 °C for 10 minutes for deactivation of the enzyme, then lyophilized to thereby obtain about 35 g of LF hydrolyzate having 18 % decomposition rate measured by the same method as in Test 9.

About 500 g of tyrosinase inhibition agent to be used for keeping freshness of food was prepared by homogeneously mixing 30 g of the resultant LF hydrolyzate, 450 g of glycine (by Wakoh Junyaku Kogyo), 20 g of lysozyme (by Wakoh Junyaku Kogyo).

Tyrosinase inhibition rate of 20 % aqueous solution of the resultant agent was 100 % measured by the same method as in Test 9.

EFFECTS OF THE INVENTION

The effects of the present invention are as follows:

- 1) LF hydrolyzate for use as an antibacterial and/or tyrosinase inhibition agent of the present invention are safety for human and animals, since it is natural antibacterial and/or tyrosinase inhibitory substance derived from hydrolysis of milk components and the like.
- 2) LF hydrolyzate for use as an antibacterial and/or tyrosinase inhibition agent of the present invention have extremely stronger antibacterial activity than unhydrolyzed LF and has remarkably potent tyrosinase inhibition activity.
- 3) LF hydrolyzate for use as an antibacterial and/or tyrosinase inhibition agent of the present invention is stable to heating, and can be provided in liquid and powdery forms, thus it has wider application.
- 4) The antibacterial and/or tyrosinase inhibition agent comprising LF hydrolyzate of the present invention can be prepared by mixing them with one or more of excipients or other medicines, inclusive of other antibacterial agents and/or other tyrosinase inhibition agents.
- 5) The antibacterial agent and the tyrosinase inhibition agent consisting of or comprising LF hydrolyzate of the present invention can be utilized as a component of various products such as cosmetics, foods, feeds and other products which are desirable to be prevented or inhibited from qualitative deterioration due to proliferation of microorganisms and/or undesirable effects of tyrosinase activity. It is specifically noted that inclusion of the antibacterial and/or tyrosinase inhibition agent consisting of or comprising LF hydrolyzate of the present invention in such products is effective not only for preservation of the products, but also effective for therapy of bacterial infection and/or pigmentation of melanine or

prevention therefrom when the products are given to human and other animals or applied to the body surface thereof.

6) The antibacterial and/or tyrosinase inhibition agent consisting of or comprising LF hydrolyzates of the present invention can be utilized for treatment of various materials, for example washing or dipping the materials in a solution of the agent so that the agent is stuck to or coated onto or impregnated into those materials, for maintenance of sanitary conditions and for prevention from deterioration in freshness thereof. It is specifically noted that the materials treated are also effective for therapy against bacterial infection, prevention therefrom, or pigmentation of melanine or prevention therefrom when they are taken into or applied onto the body surface of human or animals subject to that effective amount of LF hydrolyzate is accompanied therewith (or remained therein).

Claims

1. Lactoferrin hydrolyzate for use as an antibacterial and/or tyrosinase inhibition agent which is obtainable by hydrolysis of lactoferrin.
2. An antibacterial and/or tyrosinase inhibition agent consisting of lactoferrin hydrolyzate which are obtainable by hydrolysis of lactoferrin.
3. An antibacterial and/or tyrosinase inhibitory agent comprising an effective amount of lactoferrin hydrolyzate, for antibacterial and/or tyrosinase inhibition activity, which are obtainable by hydrolysis of a lactoferrin.
4. A composition of matter comprising the antibacterial and/or tyrosinase inhibition agent of any of the preceeding Claim comprising an effective quantity of lactoferrin hydrolyzate therein.
5. A method for treating materials with antibacterial and/or tyrosinase inhibition agent consisting of or comprising an effective amount of lactoferrin hydrolyzates for antibacterial activity and/or tyrosinase inhibition activity.

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 438 750 A3

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 90125035.7

(51) Int. Cl.⁵: A61K 37/18, A01N 63/02

(22) Date of filing: 20.12.90

(30) Priority: 23.01.90 JP 13315/90
26.06.90 JP 169636/90

(43) Date of publication of application:
31.07.91 Bulletin 91/31

(94) Designated Contracting States:
DE FR GB IT

(88) Date of deferred publication of the search report:
08.01.92 Bulletin 92/02

(71) Applicant: MORINAGA MILK INDUSTRY CO.,
LTD.
33-1, Shiba 5-chome
Minato-ku, Tokyo(JP)

(72) Inventor: Kobayashi, Susumu
No. 222 Morinaga-Kibougaoka-Ryo, 118,
Kibougaoka
Asahi-ku, Yokohama-shi, Kanagawa(JP)
Inventor: Tomita, Mamoru
1-47-6, Higashiasahina, Kanazawa-ku
Yokohama-shi, Kanagawa(JP)
Inventor: Kawase, Kouzou
761-1, Shirakuwa
Urawa-shi, Saitama(JP)

Inventor: Tamura, Yoshitaka
1-4-5, Fujizuka, Kohoku-ku
Yokohama-shi, Kanagawa(JP)
Inventor: Takase, Mitsunori
138-10, Minaminakamaru
Ohmiya-shi, Saitama(JP)
Inventor: Miyakawa, Hiroshi
4-7-21, Ohfuna
Kamakura-shi, Kanagawa(JP)
Inventor: Yamauchi, Koji
No. 405 Garden Heights Kamakura Tamatsuna,
4-2-2
Tamatsuna, Kamakura-shi, Kanagawa(JP)
Inventor: Saito, Hitoshi No. 301
Morinaga-Yurigaoka-Shataku
2-7-4, Yurigaoka
Asoh-ku, Kawasaki-shi, Kanagawa(JP)
Inventor: Abe, Hiroaki
3-43 Urugo-cho
Yokosuka-shi, Kanagawa(JP)
Inventor: Shimamura, Seichi
1558, Shinoharacho, Kohoku-ku
Yokohama-shi, Kanagawa(JP)

(74) Representative: Baillie, Iain Cameron et al
c/o Ladas & Parry Altheimer Eck 2
W-8000 München 2(DE)

(54) Lactoferrin hydrolyzate for use as an antibacterial agent and as a tyrosinase inhibition agent.

(57) Lactoferrin hydrolyzates, having a decomposition rate between 6 % - 20 % as measured by formol titration, for use as an antibacterial agent which has remarkably potent activity than unhydrolyzed lactoferrin; and lactoferrin hydrolyzates, having a decomposition rate between 4 - 50 % as measured by formol titration, for use as a tyrosinase inhibition agent, which are obtainable by the conventional method for hydrolysis with acid or enzyme, and which are stable to heating.

EP 0 438 750 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

Application Number

EP 90 12 5035

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
X	WO-A-8 604 217 (GAURI, KAILASH) * The whole document *	1-5	A 61 K 37/18 A 01 N 63/02
A	GB-A-2 168 982 (SNOW BRAND MILK PRODUCTS) * The whole document *	1-5	
A,D	JOURNAL OF DAIRY SCIENCE, vol. 67, no. 3, 1984, pages 606-613; B.J. NONNECKE et al.: "Inhibition of mastitic bacteria by bovine milk apo-lactoferrin evaluated by in vitro microassay of bacterial growth" * The whole article *	1-5	
			TECHNICAL FIELDS SEARCHED (Int. Cl.5)
			A 61 K C 07 K
INCOMPLETE SEARCH			
<p>The Search Division considers that the present European patent application does not comply with the provisions of the European Patent Convention to such an extent that it is not possible to carry out a meaningful search into the state of the art of some of the claims</p> <p>Claims searched completely : Claims searched incompletely : 5 Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>Method for treatment of the human or animal body by surgery or therapy (See art. 52(4) of the European Patent Convention)</p>			
Place of search THE HAGUE		Date of completion of the search 23-09-1991	Examiner FERNANDEZ Y BRANAS F.J.
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category : A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	



European Patent
Office

CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

- ☐ All claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for all claims.
- ☐ Only part of the claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid.
- namely claims:
- ☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirement of unity of invention and relates to several inventions or groups of inventions, namely:

See sheet -B-

- ☒ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- ☐ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid.
- namely claims:
- ☐ None of the further search fees has been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims.
- namely claims:



European Patent
Office

EP 90 12 5035 -B-

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirement of unity of invention and relates to several inventions or groups of inventions, namely:

1. Claims 1-5(partially): as far as the use of lactoferrin hydrolysate as an antibacterial agent and compositions and method thereof.
2. Claims 1-5(partially): As far as the use of lactoferrin hydrolysate as a tyrosinase inhibition agent and compositions and method thereof.